Novartis AG ADR (NVS)vsSTAAR Surgical Company (STAA)
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
STAA
STAAR Surgical Company
$26.69
-2.16%
HEALTHCARE · Cap: $1.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 23529% more annual revenue ($56.58B vs $239.44M). NVS leads profitability with a 23.9% profit margin vs -33.6%. STAA appears more attractively valued with a PEG of 0.76. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
STAA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Margin of Safety
+40.5%
Fair Value
$29.00
Current Price
$26.69
$2.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Growing faster than its price suggests
18.1% revenue growth
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -21.7% — below average capital efficiency
Earnings declined 10.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : STAA
The strongest argument for STAA centers on Debt/Equity, PEG Ratio, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : STAA
The primary concerns for STAA are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while STAA is a growth play — different risk/reward profiles.
STAA carries more volatility with a beta of 1.20 — expect wider price swings.
STAA is growing revenue faster at 18.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 37/100), backed by strong 23.9% margins. STAA offers better value entry with a 40.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →STAAR Surgical Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?